Campylobacteriosis

Moyer, Nelson P.; Holcomb, Larry A.

doi:10.1007/978-1-4612-3898-0_15

Cited by 5 publications

(6 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fresh stool samples were cultured on Skirrow's medium and incubated at 42°C for 2 days. Recovered Campylobacter isolates were identified by standard microbiological methods (20). Stool samples were also used to inoculate MacConkey, Hektoen Enteric, and thiosulfate-citrate-bile salt sucrose agars to screen for other enteric bacterial pathogens.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of antibodies reactive with Campylobacter jejuni in Egyptian diarrhea patients

Ismail

Wasfy

Oyofo

et al. 1997

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

Serum and stool samples were collected from 128 individuals: 96 diarrhea patients and 32 apparently healthy controls. Stool specimens were cultured for enteric bacterial pathogens, while sera were screened by enzyme-linked immunosorbent assay for Campylobacter jejuni-reactive antibodies. Of 28 diarrhea patients who demonstrated C. jejuni-reactive antibodies (titers, >100), 14 were culture positive for this organism. The 32 healthy controls showed significantly lower antibody titers (P < 0.05) with the exception of 10 subjects who were culture positive for C. jejuni and had reactive immunoglobulin M (IgM) (6 subjects) and IgG (7 subjects). IgA was not detected in those 10 individuals (asymptomatic). Avidity was expressed as the thiocyanate ion concentration required to inhibit 50% of the bound antibodies. The avidity was higher in symptomatic patients than asymptomatic healthy controls. IgG was less avid (0.92 M) compared to IgM (0.1 M) and IgA (1.1 M), with no correlation between antibody titer and avidity. However, the thiocyanate ion concentration required for the complete inhibition of IgG (5 M)-bound antibodies was higher than that of IgA (2 M) and IgM (3 M). This study also shows that C. jejuni antibodies were variably cross-reactive with Escherichia coli, Shigella flexneri, Shigella sonnei, and Neisseria meningitidis in addition to Campylobacter coli and Campylobacter rectus. Campylobacter jejuni is among the most common bacterial causes of acute diarrheal disease in the world (4). Sequelae of the disease may include lymphadenitis, cystitis, cholecystitis, pancreatitis, hepatitis, hemolytic uremic syndrome, peritonitis, erythema nodosum, septic arthritis, osteomyelitis, septic abortion, and Guillain-Barré syndrome (20). Several lines of evidence suggest that protective immunity can be developed against this pathogen. Spreeuwel et al. (26) and Blaser and Duncan (5) reported the presence of specific serum immunoglobulin M (IgM), IgG, and IgA in acute Campylobacter intestinal disease. Both IgM and IgG persisted for 3 months or more, whereas IgA remained elevated for 1 month or less. Healthy individuals with occupational exposure to C. jejuni produced IgM without overt disease (28). Although much information exists on the microbial characteristics of C. jejuni and disease transmission, little is known about the immune response to this infection. Blaser and coworkers (6) found IgG titers greater than 1:32 by the immunofluorescence technique in sera from convalescent subjects with positive stool cultures, whereas sera from healthy control individuals showed titers of 1:2 to 1:16. However, antibody elevation in a disease process may mediate a variety of effector mechanisms that are dependent on specificity, avidity, and affinity and may be determined largely by class or subclass and site of action (16). Many host defenses, including complement activation (25), immune elimination (2), and neutralization (3) are affected by the avidity of the participating antibody (8).

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of antibodies reactive with Campylobacter jejuni in Egyptian diarrhea patients

Ismail

Wasfy

Oyofo

et al. 1997

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

show abstract

“…melilensis isolated from the blood, synovial fluid, mitral valve or other tissucsof 104 patients with II. melilensis infection were used and identified by standard methods [4], Minimal inhibitory concentrations (MIC) were determined by broth dilu tion according to the method of Hall and Marion [5], using Muellcr-Hinton broth and an inocolum of 105 CFU/ml. The effect of antibacterial agents in combina tion was tested by the method of Schocnknccht ct al.…”

Section: Introductionmentioning

confidence: 99%

Susceptibility of <i>Brucella melitensis</i> to the New Fluoroquinolone PD 131628: Comparison with Other Drugs

Qadri

Ueno²

1993

Chemotherapy

View full text Add to dashboard Cite

The antibacterial activity of PD 131628 was determined by the broth dilution method against 105 clinical isolates of Brucella melitensis. Fifty-two and ninety-nine percent of the isolates were inhibited by 0.06 and 0.12 μg/ml of this quinolone, respectively. One strain which was resistant to 8 other fluoroquinolones, with a minimum inhibitory concentration (MIC) of > 4.0 μg/ml, did not show cross-resistance and had an MIC of 2.0 μg/ml. Of the 9 fluoroquinolones tested, PD 131628 was most inhibitory followed by CI-960. All the strains were susceptible to conventional drugs like gentamicin, rifampicin, tetracycline and trimethoprim-sulfamethoxazole, with MICs ranging between 0.12 and 1.0 μg/ml. PD 131628 did not exhibit in vitro synergy with any of the conventional drugs.

show abstract

“…Even with appropriate treatment, a patient may be ill for a month or longer, with approximately 2-10 % having one or more relapses. 11 The relapse rate is higher if the prescribed course of antibiotic therapy is discontinued before six weeks. Cases of brucellosis resulting from B. canis are similar to those caused by other Brucella species, although the symptoms are generally not as severe.…”

Section: Q Fevermentioning

confidence: 99%

Health hazard evaluation report: HETA-98-0339-2806, United States Department of Agriculture, Animal and Plant Health Inspection Service, Riverdale, Maryland.

2000

View full text Add to dashboard Cite

Campylobacteriosis

Cited by 5 publications

References 73 publications

Evaluation of antibodies reactive with Campylobacter jejuni in Egyptian diarrhea patients

Evaluation of antibodies reactive with Campylobacter jejuni in Egyptian diarrhea patients

Susceptibility of <i>Brucella melitensis</i> to the New Fluoroquinolone PD 131628: Comparison with Other Drugs

Health hazard evaluation report: HETA-98-0339-2806, United States Department of Agriculture, Animal and Plant Health Inspection Service, Riverdale, Maryland.

Contact Info

Product

Resources

About